Takeda's TAK-861 Shows Promising Results in Phase IIb Trial for Narcolepsy Type 1

Novel oral orexin receptor 2 agonist produced statistically significant and clinically meaningful improvements in wakefulness compared with placebo in patients with narcolepsy type 1.